Patient-Reported Outcomes From LIBRETTO-431: First-Line Selpercatinib Versus Chemotherapy With Pembrolizumab in RET Fusion-Positive NSCLC

Introduction: The benefit of first-line selpercatinib versus platinum-based chemotherapy with or without pembrolizumab in patients with advanced RET fusion-positive NSCLC has been previously reported. The patient-reported outcomes (PROs) from the LIBRETTO-431 trial presented here further support the...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Caicun Zhou, MD, PhD, Silvia Novello, MD, PhD, Pilar Garrido, MD, PhD, Christophe Dooms, MD, PhD, Jorge Alatorre-Alexander, MD, Niels Reinmuth, MD, Gill Worthy, PhD, Kim Cocks, PhD, Justin Williams, PhD, Hongmei Han, MS, MApSt, Minji K. Uh, PhD, Nalin Payakachat, PhD, Adrienne M. Gilligan, PhD, Koichi Goto, MD, PhD
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2025-07-01
Serija:	JTO Clinical and Research Reports
Teme:	Patient-reported outcomes (PROs) Non–small cell lung cancer (NSCLC) Selpercatinib Patient-reported tolerability
Online dostop:	http://www.sciencedirect.com/science/article/pii/S266636432500030X
Oznake:	Označite Brez oznak, prvi označite!